Recent advances in drug delivery systems for treating ocular complications of systemic diseases

Current Opinion in Ophthalmology

Volumn 20, Issue 6, 2009, Pages 511-519

  Lee, Susan S ^a,b   Hughes, Patrick M ^c   Robinson, Michael R ^c  

^a University of Southern California ^*  (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c ALLERGAN INC   (United States)

Author keywords

Corticosteroids; Diabetic retinopathy; Drug delivery; Inflammation; Macular edema; Retinitis; Uveitis; Vascular endothelial derived growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CIDOFOVIR; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; FOSCARNET; GANCICLOVIR; ILUVIEN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ABSENCE OF SIDE EFFECTS; CATARACT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAOCULAR PRESSURE; LASER COAGULATION; NEPHROTOXICITY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETINITIS; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; SYMPATHETIC OPHTHALMIA; TEMPORAL ARTERITIS; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; EYE DISEASES; GLUCOCORTICOIDS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74249085606     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328330ccb9     Document Type: Review

References (63)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
2. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447-9, 1449.e1-10 This landmark, 2-year, multicenter, randomized clinical trial showed that the efficacy and safety of focal/grid photocoagulation were significantly better than with intravitreal triamcinolone.
3. Beck RW, Edwards AR, Aiello LP, et al., Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245-251. The 3-year data from this extension study showed no long-term efficacy or safety advantages of intravitreal triamcinolone relative to focal/grid photocoagulation.
4. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res 2009; 41:124-135. A thorough recent review of drug delivery systems and pharmacological agents used in the treatment of ocular diseases.
5. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 2009; 26:770-784.
6. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008; 23;CD005656. This meta-analysis of published randomized, controlled clinical trials indicated that intravitreally injected or surgically implanted corticosteroids can improve visual outcomes in patients with persistent or refractory DME.
7. Abraldes MJ, Fernández M, Gómez-Ulla F. Intravitreal triamcinolone in diabetic retinopathy. Curr Diabetes Rev 2009; 5:18-25.
8. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina 2009; 29:207-213.
9. Jonisch J, Lai JC, Deramo VA, et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br JOphthalmol 2008; 92:1051-1054.
10. Krah JL, Krimmel D, Dodwell D. Sterile endophthalmitis secondary to intravitreal Triesence (triamcinolone acetonide). Invest Ophthalmol Vis Sci 2009; 50:E-abstract 3565.
11. Hauser D, Bukelman A, Pokroy R, et al. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008; 28:825-830.
12. Karacorlu M, Ozdemir H, Senturk F, et al. Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol 2008; 18:601-608.
13. Wickremasinghe SS, Rogers SL, Gillies MC, et al. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 2008; 49:4707-4711.
14. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992; 110:259-266.
15. Kuppermann BD, Blumenkranz MS, Haller JA, et al., Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125:309-317.
16. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29:46-51. This randomized, prospective, multicenter, controlled pilot study in patients with macular edema due to diverse causes demonstrated the safety and efficacy of DEX-PS-DDS inserted using an applicator system or by pars plana incisional placement.
17. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5:1039-1046.
18. Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA Jr, Scott IU. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 2009; 147:1022-1030. A multicenter, open-label, nonrandomized study demonstrating the efficacy of intravitreal bevacizumab in patients with DME associated with severe capillary loss.
19. Jiang Y, Liang X, Li X, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2008 [Epub ahead of print]
20. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28:1053-1060.
21. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246:1699-1705.
22. Ornek K, Ornek N. Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2008; 24:403-407.
23. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008; 28:1314-1318.
24. Romano MR, Gibran SK, Marticorena J, et al. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye 2008 [Epub ahead of print]
25. Astam N, Batoǧlu F, Ozmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol 2008; [Epub ahead of print] This 3-month retrospective study demonstrated the efficacy of intravitreal bevacizumab in patients with macular edema due to RVO, but not in patients with macular edema due to diabetic retinopathy.
26. Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36:449-454.
27. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009; 29: 516-522. This study demonstrated that intravitreal bevacizumab treatment, as an adjunct to panretinal photocoagulation was effective in reducing macular thickness in patients with high-risk PDR only when clinically significant macular edema was absent.
28. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009; 40:68-70.
29. Jun Lee S, Jun Koh H. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther 2009; [Epub ahead of print]
30. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular edema. Br J Ophthalmol 2009; 93:144-149.
31. Yau JW, Lee P, Wong TY, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38:904-910.
32. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98:271-282.
33. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986; 104:34-41.
34. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102:1425-1433.
35. Chung EJ, Lee H, Koh HJ. Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008; 246:967-974. A 6-month randomized trial demonstrating better visual outcomes with intravitreal triamcinolone acetonide versus arteriovenous sheathotomy after 1 month of treatment but similar outcomes at 3 and 6 months.
36. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008; 146:285-291. This 12-month, prospective study showed that the fluocinolone acetonide sustained drug delivery system was effective for the treatment macular edema in CRVO patients but was associated with a high incidence of cataracts.
37. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009; 50:1025-1032. This prospective clinical trial demonstrated improvement in vision and retinal thickness and decreased aqueous VEGF levels after at least 3 monthly intravitreal injections of bevacizumab.
38. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93:452-456. A 12-month, prospective clinical trial demonstrating that treatment with intravitreal bevacizumab was safe and effective but limited by a short duration of action and high recurrence rate.
39. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for nonischaemic branch retinal vein occlusion. Ophthalmologica 2009; 223:124-127. This was a 6-month trial demonstrating the efficacy and safety of intravitreal bevacizumab injections for the treatment of macular edema caused by nonischemic BRVO.
40. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for nonischaemic central retinal vein occlusion. Acta Ophthalmol 2009; 87:77-81. This 6-month trial demonstrated the efficacy and safety of intravitreal bevacizumab injections for the treatment of macular edema caused by nonischemic CRVO.
41. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147:298-306.
42. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115:e47-e54.
43. Jabs DA. AIDS and ophthalmology, 2008. Arch Ophthalmol 2008; 126:1143-1146.
44. Banker AS. Posterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome. Indian J Ophthalmol 2008; 56: 377-383.
45. Holland GN, Vaudaux JD, Shiramizu KM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol 2008; 145:12-22.
46. Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.
47. Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008; 145:397-408.
48. Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 2007; 14:66-71.
49. Susan S. Lee, Peng Yuan, Michael R. Robinson, Ocular Implants for Drug Delivery in Encyclopedia of Biomaterials and Biomedical Engineering by Gary E. Wnek and Gary L. Bowlin, Informa Healthcare 2004; 1105-1119.
50. Schreiber A, Harter G, Schubert A, et al. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009; 10:191-209.
51. Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004; 88:1159-1162.
52. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111:491-500.
53. Williams GA, Haller JA, Kuppermann BD; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; [Epub ahead of print] This subgroup analysis of data from a prospective, multicenter, randomized, controlled study demonstrated the efficacy and safety of DEX-PS-DDS in patients with persistent macular edema resulting from uveitis or Irvine-Gass syndrome uveitis.
54. Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol 2008; 18:429-434.
55. Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008; 126:200-205.
56. Roesel M, Tappeiner C, Heinz C, et al. Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis. Am J Ophthalmol 2009; 147:406-412.
57. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191-1201.
58. Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol 2009; 20:99-103.
59. Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Am J Ophthalmol 2008; 146:589-594. A 12-month, retrospective, single-center case series study demonstrating the efficacy of the FA implant in patients with uveitis.
60. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (RetisertTM) reimplantation for chronic noninfectious posterior uveitis. Retina 2008; 28:1280-1288.
61. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009 [Epub ahead of print]
62. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007; 18:235-239.
63. Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009; 16:10-16.